CA2323604A1 - Interferon alpha plasmids and delivery systems, and methods of making and using the same - Google Patents

Interferon alpha plasmids and delivery systems, and methods of making and using the same Download PDF

Info

Publication number
CA2323604A1
CA2323604A1 CA002323604A CA2323604A CA2323604A1 CA 2323604 A1 CA2323604 A1 CA 2323604A1 CA 002323604 A CA002323604 A CA 002323604A CA 2323604 A CA2323604 A CA 2323604A CA 2323604 A1 CA2323604 A1 CA 2323604A1
Authority
CA
Canada
Prior art keywords
plasmid
sequence
composition
coding sequence
interferon alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323604A
Other languages
English (en)
French (fr)
Inventor
Jeff Nordstrom
Federica Pericle
Alain Rolland
Robert Ralston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323604A1 publication Critical patent/CA2323604A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA002323604A 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same Abandoned CA2323604A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7865498P 1998-03-19 1998-03-19
US60/078,654 1998-03-19
PCT/US1999/005394 WO1999047678A2 (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA2323604A1 true CA2323604A1 (en) 1999-09-23

Family

ID=22145430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323604A Abandoned CA2323604A1 (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same

Country Status (5)

Country Link
EP (1) EP1064383A2 (de)
JP (1) JP2002506647A (de)
AU (1) AU3000399A (de)
CA (1) CA2323604A1 (de)
WO (1) WO1999047678A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175897A1 (en) * 2000-04-14 2003-09-18 Thayer Edward C. Human interferon, Zinf2
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
DK1305437T3 (da) 2000-07-31 2010-12-13 Biolex Therapeutics Inc Ekspression af biologisk aktive polypeptider i andemad
EP1195436A1 (de) * 2000-10-04 2002-04-10 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Expressionsvektoren mit veränderter ColE1 Replikationsursprung zur Kontrolle der Plasmidkopienzahl
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
EP2377402A1 (de) 2003-05-01 2011-10-19 Medgenics, Inc. Genetisch modifiziertes dermisches mikroorgan-ausdrückendes Interferon
WO2007084364A2 (en) * 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
JP2010504909A (ja) 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
WO2009140206A1 (en) * 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
AU2011268458B2 (en) 2010-06-15 2014-06-12 Medgenics Medical Israel Ltd. Long lasting drug formulations
KR102674807B1 (ko) 2011-12-12 2024-06-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
AU2018246292A1 (en) 2017-03-31 2019-10-10 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (NMSC)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
WO1997000085A1 (en) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
WO1997033998A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
EP0956301A2 (de) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 genexpressions- und transfersysteme und verwendungen
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses

Also Published As

Publication number Publication date
WO1999047678A3 (en) 1999-12-09
WO1999047678A9 (en) 2000-11-09
AU3000399A (en) 1999-10-11
JP2002506647A (ja) 2002-03-05
EP1064383A2 (de) 2001-01-03
WO1999047678A2 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
Toda et al. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
Kramm et al. Gene therapy for brain tumors
US6399588B1 (en) Cancer treatment method utilizing plasmids suitable for IL-2 expression
US6051428A (en) Rapid production of autologous tumor vaccines
US6034072A (en) IL-2 gene expression and delivery systems and uses
CA2323604A1 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
AU675948B2 (en) Bystander effect tumoricidal therapy
JPH10513362A (ja) 生体活性な融合タンパク質および先在する腫瘍の治療
Tamura et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer
WO1998034952A9 (en) Il-2 gene expression and delivery systems and uses
KR102056066B1 (ko) 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물
Shi et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF
JP2003508016A (ja) Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
Herrmann Cancer gene therapy: principles, problems, and perspectives
KR20240013750A (ko) Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도
CA2337496A1 (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
WO2000006759A9 (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
Avalosse et al. Gene therapy for cancer
Davidoff et al. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
US20220213160A1 (en) Protein heterodimer and use thereof
Missol et al. Introduction of murine Il-4 gene into B16 (F10) melanoma tumors by direct gene transfer with DNA-liposome complexes
CZ20003807A3 (cs) DNA konstrukt, izolovaná molekula nukleové kyseliny, homologně rekombinantní buňka a její použití, způsob pozměnění exprese endogenního G-CSF genu a způsob produkce G-CSF
CN109748974B (zh) 一种基因修饰的树突状细胞疫苗的制备及应用
Paul et al. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12)
Eslahi et al. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead